Multiple Sclerosis Drugs Market Global Report 2020-30 from the author provides the strategists, marketers and senior management with the critical information they need to assess the global multiple sclerosis drugs market.
Reasons to Purchase
Description:
Where is the largest and fastest growing market for the multiple sclerosis drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Multiple Sclerosis Drugs market global report from the author answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider multiple sclerosis drugs market, and compares it with other markets.
Scope
Markets Covered: 1) By Drug Class: Immunomodulators; Immunosuppressants; Interferons; Others; 2) By Distribution Channels: Hospital Pharmacy; Retail Pharmacy; Online Stores; 3) By Route Of Administration: Oral Drugs; Parenteral Drugs
Companies Mentioned: Biogen; Novartis; Roche; Bayer HealthCare; Pfizer, Inc.
Countries: Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA and Australia
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 3 working days of order.
Description:
Where is the largest and fastest growing market for the multiple sclerosis drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Multiple Sclerosis Drugs market global report from the author answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider multiple sclerosis drugs market, and compares it with other markets.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
- Market segmentations break down market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
- Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
- The multiple sclerosis drugs market section of the report gives context. It compares the multiple sclerosis drugs market with other segments of the multiple sclerosis drugs market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, multiple sclerosis drugs indicators comparison.
Scope
Markets Covered: 1) By Drug Class: Immunomodulators; Immunosuppressants; Interferons; Others; 2) By Distribution Channels: Hospital Pharmacy; Retail Pharmacy; Online Stores; 3) By Route Of Administration: Oral Drugs; Parenteral Drugs
Companies Mentioned: Biogen; Novartis; Roche; Bayer HealthCare; Pfizer, Inc.
Countries: Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA and Australia
Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Table of Contents
1. Executive Summary2. Multiple Sclerosis Drugs Market Characteristics26. Key Mergers And Acquisitions In The Multiple Sclerosis Drugs Market27. Multiple Sclerosis Drugs Market Trends And Strategies28. Multiple Sclerosis Drugs Market Future Outlook and Potential Analysis
3. Multiple Sclerosis Drugs Market Size And Growth
4. Multiple Sclerosis Drugs Market Segmentation
5. Multiple Sclerosis Drugs Market Regional And Country Analysis
6. Asia-Pacific Multiple Sclerosis Drugs Market
7. China Multiple Sclerosis Drugs Market
8. India Multiple Sclerosis Drugs Market
9. Japan Multiple Sclerosis Drugs Market
10. Australia Multiple Sclerosis Drugs Market
11. Indonesia Multiple Sclerosis Drugs Market
12. South Korea Multiple Sclerosis Drugs Market
13. Western Europe Multiple Sclerosis Drugs Market
14. UK Multiple Sclerosis Drugs Market
15. Germany Multiple Sclerosis Drugs Market
16. France Multiple Sclerosis Drugs Market
17. Eastern Europe Multiple Sclerosis Drugs Market
18. Russia Multiple Sclerosis Drugs Market
19. North America Multiple Sclerosis Drugs Market
20. USA Multiple Sclerosis Drugs Market
21. South America Multiple Sclerosis Drugs Market
22. Brazil Multiple Sclerosis Drugs Market
23. Middle East Multiple Sclerosis Drugs Market
24. Africa Multiple Sclerosis Drugs Market
25. Multiple Sclerosis Drugs Market Competitive Landscape And Company Profiles
29. Appendix
Executive Summary
The multiple sclerosis drugs market consists of sale of multiple sclerosis drugs and related services. Multiple sclerosis (MS) is an autoimmune disease where the immune system attacks the protective fat layer called myelin, around the nerve fibers and causes problems with muscle control, vision and other body functions. It is a disease that affects brain, spinal cord and the optic nerves resulting in loss of balance, coordination and compromised vision. The disease can result in long term disability.The global multiple sclerosis drugs market was worth $20.83 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 5.20% and reach $25.52 billion by 2023.
The multiple sclerosis drugs market has been geographically segmented into North America, Western Europe, Asia-Pacific, Eastern Europe, South America and Middle East & Africa. North America is expected to be the largest region in the forecast period.
The multiple sclerosis drugs market covered in this report is segmented by drug class into immunomodulators, immunosuppressants, interferons, others. It is also segmented by distribution channels into hospital pharmacy, retail pharmacy, and online stores and by route of administration: oral drugs and, parenteral drugs.
The growth of multiple sclerosis drugs market is aided by the support from government as well as non-government organization. The government and non-government organizations fund several schemes and programs to offer their support to enhance the quality of life of people affected with multiple sclerosis (MS). For instance, in 2019, the government of Alberta in partnership with the department of Economic Development, Trade and Tourism in Canada invested $1million towards the Canadian Prospective Cohort Study to Understand Progression in Multiple Sclerosis (CanProCo) to support the research and innovations to enhance understanding and treatment for MS disease. CanProCo is an initiative to consolidate the efforts of nearly 50 MS researchers from various disciplines across Canada. The initiative was further funded by the Canada Brain Research, Biogen Canada and the MS Society of Canada, as well as Hoffmann-La Roche Limited (Roche Canada) to raise a total of $10 million. Appropriate financial support from the government and non-government organizations boosts the growth of multiple sclerosis drugs market.
The high cost of drugs to treat multiple sclerosis (MS) restricts the growth of multiple sclerosis drugs market. The MS is a cureless disease with high chances of disability and requires lifelong treatment. Despite the heavy competition among the drug companies, the cost of MS drugs is high, increasing the overall cost of treatment. The companies operating in the multiple sclerosis drugs market often have to work towards reducing the cost of these drugs to justify its cost-effectiveness to its consumers. As reported by Institute for Clinical and Economic Review (ICER) in 2017, the MS drugs costs roughly between $63,000 and $104,000 annually. For instance, in 2019, after receiving criticism by National Multiple Sclerosis Society on the high price of Vumerity, a drug to treat relapse MS, Biogen and Alkermes had to reduce the prices of the drug to $88,000 per year in order to make it affordable to the patients. The high cost of drugs, which are required lifelong negatively affects the growth of the multiple sclerosis drugs market.
The companies are rapidly intensifying their efforts to focus on new product launches to cater to the rising demands for MS drugs. The multiple sclerosis requires a lifelong treatment, which increases the overall cost of treating a patient. In order to provide better and effective treatment companies in the multiple sclerosis market are developing drugs specific to the treatment of multiple sclerosis. Following the trend, in 2019, FDA approved Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribrine) for the treatment of relapsing remitting multiple sclerosis (RRMS), and active secondary progressive multiple sclerosis (SPMS). Both the drugs were launched as an easy-to-consume oral drug.
In 2019, Bristol-Myers Squibb, a USA based pharmaceutical company, acquired Celgene for $74billion. Through the acquisition Bristol-Myers Squibb aims to increase its product portfolio by utilizing the existing products of Celgene along with its technical and pipeline support. Ozanimod is one of the Celgene’s pipelined drugs for the treatment of relapsing multiple sclerosis. The drug is currently in phase III clinical trials to be approved by FDA. Celgene is a USA based producer and marketer of medicines for cancer and inflammatory disorders such as multiple sclerosis.
Major players in the market are Biogen, Novartis, Roche, Bayer HealthCare, Pfizer, Inc., Merck & Co., Inc., Sanofi, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline and Acorda Therapeutics Inc.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Biogen
- Novartis
- Roche
- Bayer HealthCare
- Pfizer, Inc.
- Merck & Co., Inc.
- Sanofi
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline
- Acorda Therapeutics Inc.
- Actelion Pharmaceuticals (Johnson & Johnson)
- EMD Serono (Merck KGaA)
- AbbVie, Inc.
- Betaseron
- CinnoVex
- Extavia
- Rebif
- Tysabr
Methodology
LOADING...
